Australia seems poised to experience innovative therapy for excess weight: Retatrutide. This new dual agonist – working on both GLP-1 and GIP receptors – shows significant outcomes in global research, suggesting considerable reductions in BMI. While availability remains with TGA, a number of individuals battling weight-related health concerns a